Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma

TYPE OF SARCOMA: Ewing’s Family (including PNET), OsteosarcomaSynovial Sarcoma, Leiomyosarcoma, Rhabdomyosarcoma (including alveolar, embryonal and pleomorphic), Liposarcoma (all variants), Malignant Fibrous Histiocytoma, Peripheral Nerve Sheath (including MPNST, neurofibrosarcoma, schwannoma), Fibrosarcoma, Angiosarcoma (all variants), Desmoid Tumor, GI Stromal (c-kit negative only)
DRUG: Imatinib Mesylate (Gleevec)
ACCRUAL STATUS: Completed

OVERALL STUDY PRINCIPAL INVESTIGATOR:
Lee J. Helman, MD
National Cancer Institute (NCI)

CLINICALTRIALS.GOV IDENTIFIER: NCT00031915

FOR STUDY DETAILS AND ELIGIBILITY CRITERIA: CLINICALTRIALS.GOV

To learn more about this study or to contact the study research staff: